The main conclusions of this study were that the proteomic gene expression profile could better predict the durable response of NSCLC patients to anti-programmed cell death-1 (anti-PD-1)/programmed cell death ligand 1 (anti-PD-L1) therapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.